President Trump has proposed significant tariffs, potentially up to 200%, on imported pharmaceuticals, a sector previously largely exempt from such measures. The stated aim is to boost U.S. domestic drug manufacturing and reduce reliance on foreign supply chains, particularly after the COVID-19 experience. However, experts warn that these tariffs could lead to higher drug prices for consumers, disrupt complex supply chains, and create shortages, especially for low-margin generic drugs. While some companies are investing in U.S. production, the feasibility of fully domestic supply chains remains a challenge due to cost and ingredient sourcing.

Source: Newsmax